Study of UGT1A1*27 gene polymorphism for irinotecan therapy

Study of UGT1A1*27 gene polymorphism for irinotecan therapy - Study of UGT1A1*27 for irinotecan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006164

Enrollment

111

Registered

2011-08-12

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) histologicaly or cytologicaly confirmed lung cancer 2) scheduled the dose of Irinotecan therapy as follows: single >= 80mg/m2 combination >= 50mg/m2 radiation with single >= 50mg/m2 radiation with combination >= 40mg/m2 3) age >= 20 year old 4) ECOG PS 0-2 5) Written informed consent

Exclusion criteria

Exclusion criteria: 1) interstitial pneumonia in chest X-ray 2) with active infection 3) with active the other malignancies 4) pregnancy or possible pregnancy 5) mental diesease difficult to attend the study 6) high fever >= 38 degree 7) severe complication: myocardial infarction within 3 months, uncontrolled angina pectoris, heart failure, diabetes mellitus, hypertension 8) diarrhea 9) paralysis of intestine or ileus

Design outcomes

Primary

Measure	Time frame
Relationship between UGT1A1*27 gene polymorphism and irinotecan adverse effects	—

Countries

Japan

Contacts

Public ContactMinoru Fukuda

Nagasaki University Clinical Oncology centre

mifukuda258@nifty.com095-819-7779

Outcome results